Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

TG Therapeutics Inc (NASDAQ:TGTX)

12.20
Delayed Data
As of Jul 21
 +0.50 / +4.27%
Today’s Change
4.10
Today|||52-Week Range
15.35
+162.37%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$814.7M

Company Description

TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. It also involves developing TG-1101 and TGR-1202 therapies targeting hematological malignancies. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY.

Contact Information

TG Therapeutics, Inc.
2 Gansevoort Street
New York New York 10014
P:(212) 554-4484
Investor Relations:
(212) 554-4351

Employees

Shareholders

Mutual fund holders27.47%
Other institutional26.17%
Individual stakeholders10.23%

Top Executives

Michael Sean WeissExecutive Chairman, President & CEO
Sean A. PowerChief Financial Officer, Secretary & Treasurer
Hari MiskinVice President-Business Development
Jenna A. BoscoVice President-Investor Relations
Robert NiecestroExecutive Vice President-Clinical & Regulatory